Spire Wealth Management Has $53,000 Position in InMode Ltd. (NASDAQ:INMD)

Spire Wealth Management trimmed its holdings in shares of InMode Ltd. (NASDAQ:INMDFree Report) by 59.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 1,744 shares of the healthcare company’s stock after selling 2,527 shares during the period. Spire Wealth Management’s holdings in InMode were worth $53,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. Exencial Wealth Advisors LLC lifted its stake in InMode by 23.6% during the third quarter. Exencial Wealth Advisors LLC now owns 8,356 shares of the healthcare company’s stock worth $255,000 after purchasing an additional 1,598 shares during the period. Oppenheimer & Co. Inc. lifted its position in shares of InMode by 41.9% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 13,570 shares of the healthcare company’s stock worth $413,000 after buying an additional 4,009 shares during the period. Boston Partners boosted its stake in InMode by 3.6% in the 3rd quarter. Boston Partners now owns 555,155 shares of the healthcare company’s stock valued at $16,910,000 after buying an additional 19,151 shares in the last quarter. Kestra Private Wealth Services LLC bought a new stake in InMode in the third quarter valued at $218,000. Finally, Marco Investment Management LLC acquired a new position in InMode during the third quarter worth $241,000. 65.49% of the stock is currently owned by institutional investors and hedge funds.

InMode Stock Up 2.0 %

Shares of NASDAQ:INMD opened at $26.49 on Tuesday. InMode Ltd. has a 12 month low of $18.57 and a 12 month high of $48.25. The firm has a market cap of $2.20 billion, a P/E ratio of 12.61 and a beta of 2.22. The company’s 50-day moving average price is $22.69 and its two-hundred day moving average price is $27.56.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on INMD. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $22.00 target price on shares of InMode in a report on Thursday, December 7th. TheStreet lowered shares of InMode from a “b-” rating to a “c+” rating in a research report on Thursday, October 19th. Barclays dropped their price objective on shares of InMode from $33.00 to $32.00 and set an “overweight” rating for the company in a report on Thursday, January 18th. Finally, UBS Group reiterated a “neutral” rating and issued a $24.00 target price (down previously from $52.00) on shares of InMode in a research note on Friday, November 3rd. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $36.83.

View Our Latest Stock Analysis on InMode

About InMode

(Free Report)

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.

Read More

Want to see what other hedge funds are holding INMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InMode Ltd. (NASDAQ:INMDFree Report).

Institutional Ownership by Quarter for InMode (NASDAQ:INMD)

Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.